A single-subject method to detect pathways enriched with alternatively spliced genes

Alfred Grant Schissler, Dillon Aberasturi, Colleen Kenost, Yves A Lussier

Research output: Contribution to journalArticle

Abstract

RNA-Sequencing data offers an opportunity to enable precision medicine, but most methods rely on gene expression alone. To date, no methodology exists to identify and interpret alternative splicing patterns within pathways for an individual patient. This study develops methodology and conducts computational experiments to test the hypothesis that pathway aggregation of subject-specific alternatively spliced genes (ASGs) can inform upon disease mechanisms and predict survival. We propose the N-of-1-pathways Alternatively Spliced (N1PAS) method that takes an individual patient's paired-sample RNA-Seq isoform expression data (e.g., tumor vs. non-tumor, before-treatment vs. during-therapy) and pathway annotations as inputs. N1PAS quantifies the degree of alternative splicing via Hellinger distances followed by two-stage clustering to determine pathway enrichment. We provide a clinically relevant “odds ratio” along with statistical significance to quantify pathway enrichment. We validate our method in clinical samples and find that our method selects relevant pathways (p < 0.05 in 4/6 data sets). Extensive Monte Carlo studies show N1PAS powerfully detects pathway enrichment of ASGs while adequately controlling false discovery rates. Importantly, our studies also unveil highly heterogeneous single-subject alternative splicing patterns that cohort-based approaches overlook. Finally, we apply our patient-specific results to predict cancer survival (FDR < 20%) while providing diagnostics in pursuit of translating transcriptome data into clinically actionable information. Software available at https://github.com/grizant/n1pas/tree/master.

Original languageEnglish (US)
Article number414
JournalFrontiers in Genetics
Volume10
Issue numberMAY
DOIs
StatePublished - Jan 1 2019

Fingerprint

Recombinant DNA
Alternative Splicing
RNA Isoforms
RNA Sequence Analysis
Precision Medicine
Survival
Transcriptome
Cluster Analysis
Neoplasms
Software
Odds Ratio
Gene Expression
Therapeutics

Keywords

  • Alternative splicing
  • Hellinger distance
  • Isoform
  • Local false discovery rate
  • Pathways
  • Precision medicine
  • RNA-Seq
  • Systems biology

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Genetics(clinical)

Cite this

A single-subject method to detect pathways enriched with alternatively spliced genes. / Schissler, Alfred Grant; Aberasturi, Dillon; Kenost, Colleen; Lussier, Yves A.

In: Frontiers in Genetics, Vol. 10, No. MAY, 414, 01.01.2019.

Research output: Contribution to journalArticle

Schissler, Alfred Grant ; Aberasturi, Dillon ; Kenost, Colleen ; Lussier, Yves A. / A single-subject method to detect pathways enriched with alternatively spliced genes. In: Frontiers in Genetics. 2019 ; Vol. 10, No. MAY.
@article{c2555e6a3b0746ada1050c879503beb5,
title = "A single-subject method to detect pathways enriched with alternatively spliced genes",
abstract = "RNA-Sequencing data offers an opportunity to enable precision medicine, but most methods rely on gene expression alone. To date, no methodology exists to identify and interpret alternative splicing patterns within pathways for an individual patient. This study develops methodology and conducts computational experiments to test the hypothesis that pathway aggregation of subject-specific alternatively spliced genes (ASGs) can inform upon disease mechanisms and predict survival. We propose the N-of-1-pathways Alternatively Spliced (N1PAS) method that takes an individual patient's paired-sample RNA-Seq isoform expression data (e.g., tumor vs. non-tumor, before-treatment vs. during-therapy) and pathway annotations as inputs. N1PAS quantifies the degree of alternative splicing via Hellinger distances followed by two-stage clustering to determine pathway enrichment. We provide a clinically relevant “odds ratio” along with statistical significance to quantify pathway enrichment. We validate our method in clinical samples and find that our method selects relevant pathways (p < 0.05 in 4/6 data sets). Extensive Monte Carlo studies show N1PAS powerfully detects pathway enrichment of ASGs while adequately controlling false discovery rates. Importantly, our studies also unveil highly heterogeneous single-subject alternative splicing patterns that cohort-based approaches overlook. Finally, we apply our patient-specific results to predict cancer survival (FDR < 20{\%}) while providing diagnostics in pursuit of translating transcriptome data into clinically actionable information. Software available at https://github.com/grizant/n1pas/tree/master.",
keywords = "Alternative splicing, Hellinger distance, Isoform, Local false discovery rate, Pathways, Precision medicine, RNA-Seq, Systems biology",
author = "Schissler, {Alfred Grant} and Dillon Aberasturi and Colleen Kenost and Lussier, {Yves A}",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fgene.2019.00414",
language = "English (US)",
volume = "10",
journal = "Frontiers in Genetics",
issn = "1664-8021",
publisher = "Frontiers Media S. A.",
number = "MAY",

}

TY - JOUR

T1 - A single-subject method to detect pathways enriched with alternatively spliced genes

AU - Schissler, Alfred Grant

AU - Aberasturi, Dillon

AU - Kenost, Colleen

AU - Lussier, Yves A

PY - 2019/1/1

Y1 - 2019/1/1

N2 - RNA-Sequencing data offers an opportunity to enable precision medicine, but most methods rely on gene expression alone. To date, no methodology exists to identify and interpret alternative splicing patterns within pathways for an individual patient. This study develops methodology and conducts computational experiments to test the hypothesis that pathway aggregation of subject-specific alternatively spliced genes (ASGs) can inform upon disease mechanisms and predict survival. We propose the N-of-1-pathways Alternatively Spliced (N1PAS) method that takes an individual patient's paired-sample RNA-Seq isoform expression data (e.g., tumor vs. non-tumor, before-treatment vs. during-therapy) and pathway annotations as inputs. N1PAS quantifies the degree of alternative splicing via Hellinger distances followed by two-stage clustering to determine pathway enrichment. We provide a clinically relevant “odds ratio” along with statistical significance to quantify pathway enrichment. We validate our method in clinical samples and find that our method selects relevant pathways (p < 0.05 in 4/6 data sets). Extensive Monte Carlo studies show N1PAS powerfully detects pathway enrichment of ASGs while adequately controlling false discovery rates. Importantly, our studies also unveil highly heterogeneous single-subject alternative splicing patterns that cohort-based approaches overlook. Finally, we apply our patient-specific results to predict cancer survival (FDR < 20%) while providing diagnostics in pursuit of translating transcriptome data into clinically actionable information. Software available at https://github.com/grizant/n1pas/tree/master.

AB - RNA-Sequencing data offers an opportunity to enable precision medicine, but most methods rely on gene expression alone. To date, no methodology exists to identify and interpret alternative splicing patterns within pathways for an individual patient. This study develops methodology and conducts computational experiments to test the hypothesis that pathway aggregation of subject-specific alternatively spliced genes (ASGs) can inform upon disease mechanisms and predict survival. We propose the N-of-1-pathways Alternatively Spliced (N1PAS) method that takes an individual patient's paired-sample RNA-Seq isoform expression data (e.g., tumor vs. non-tumor, before-treatment vs. during-therapy) and pathway annotations as inputs. N1PAS quantifies the degree of alternative splicing via Hellinger distances followed by two-stage clustering to determine pathway enrichment. We provide a clinically relevant “odds ratio” along with statistical significance to quantify pathway enrichment. We validate our method in clinical samples and find that our method selects relevant pathways (p < 0.05 in 4/6 data sets). Extensive Monte Carlo studies show N1PAS powerfully detects pathway enrichment of ASGs while adequately controlling false discovery rates. Importantly, our studies also unveil highly heterogeneous single-subject alternative splicing patterns that cohort-based approaches overlook. Finally, we apply our patient-specific results to predict cancer survival (FDR < 20%) while providing diagnostics in pursuit of translating transcriptome data into clinically actionable information. Software available at https://github.com/grizant/n1pas/tree/master.

KW - Alternative splicing

KW - Hellinger distance

KW - Isoform

KW - Local false discovery rate

KW - Pathways

KW - Precision medicine

KW - RNA-Seq

KW - Systems biology

UR - http://www.scopus.com/inward/record.url?scp=85067856030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067856030&partnerID=8YFLogxK

U2 - 10.3389/fgene.2019.00414

DO - 10.3389/fgene.2019.00414

M3 - Article

VL - 10

JO - Frontiers in Genetics

JF - Frontiers in Genetics

SN - 1664-8021

IS - MAY

M1 - 414

ER -